EXCLUSIVE LICENSE AGREEMENTExclusive License Agreement • February 25th, 2016 • RedHill Biopharma Ltd. • Pharmaceutical preparations • London
THIS EXCLUSIVE LICENSE AGREEMENT is made and entered into as of March, __ 2015 (the “Effective Date”), by and between Apogee Biotechnology Corp., a Pennsylvania corporation (“Apogee”) and RedHill Biopharma Ltd., an Israeli company (“RedHill”). Apogee and RedHill each may be referred to herein individually as a “Party,” or collectively as the “Parties”.
Changed Order 4.1 to Clinical Services Agreement Sponsor’s study drug RHB-104Services Agreement • February 25th, 2016 • RedHill Biopharma Ltd. • Pharmaceutical preparations
AMENDMENT # 3RedHill Biopharma Ltd. • February 25th, 2016 • Pharmaceutical preparations
THE SYMBOL "[****]" DENOTES PLACES WHERE PORTIONS OF THIS DOCUMENT HAVE BEEN OMIITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. SUCH MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION
CLINICAL TRIALS GLOBAL MASTER SERVICES AGREEMENT AMENDMENT NO. 2Master Services Agreement • February 25th, 2016 • RedHill Biopharma Ltd. • Pharmaceutical preparations
This Amendment No. 2 is made effective as of the date last signed below (“Amendment No. 2 Effective Date”) by and between RedHill Biopharma, Ltd. (“Client”) and Quest Diagnostics Clinical Laboratories, Inc. (“Quest Diagnostics”). This Amendment No. 2 amends the Clinical Trials Global Master Services Agreement dated 27-December-2012 (the “Agreement”) as amended by Amendment No. 1 effective June 20, 2014 (“Amendment No.1”) to which both Client and Quest Diagnostics Client are parties. Client and Quest Diagnostics shall be referred together as the ”Parties”.
Change Order 5 to Clinical Services Agreement Client’s study drug RHB-104RedHill Biopharma Ltd. • February 25th, 2016 • Pharmaceutical preparations
This Change Order 5 (“Change Order”) to the Clinical Services Agreement signed 15 June 2011 (“Clinical Services Agreement”), is by and among:
